Abstract
Buprenorphine was evaluated for its ability to act as a kappa opioid antagonist in rats responding under a fixed-ratio 30 schedule of food presentation both before and after the induction of morphine tolerance. Before the induction of morphine tolerance, both buprenorphine and the selective kappa agonist bremazocine decreased rates of responding in a dose-dependent manner, and buprenorphine (0.03 and 0.3 mg/kg) failed to antagonize bremazocine's rate-decreasing effects. Following the induction of morphine tolerance, the bremazocine dose-effect curve was unaffected, but a profound cross-tolerance developed to buprenorphine. Furthermore, buprenorphine (0.03, 0.3 and 1.0 mg/kg) produced a dose-dependent antagonism of the rate-decreasing effects of bremazocine in the morphine-tolerant rats. These results support the hypothesis that buprenorphine has antagonist activity at kappa opioid receptors.
This is a preview of subscription content, log in via an institution to check access.
References
Cowan A, Lewis JW, McFarlane JR (1977) Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 60:537–545
Dum J, Blasig J, Herz A (1981) Buprenorphine: demonstration of physical dependence liability. Eur J Pharmacol 70:293–300
Dykstra LA (1985) Effects of buprenorphine on shock titration in squirrel monkeys. J Pharmacol Exp Ther 235:20–25
Gmerek DE, Dykstra LA, Woods JH (1987) Kappa opioids in Rhesus monkeys. III. Dependence associated with chronic administration. J Pharmacol Exp Ther 242:428–436
Leander JD (1983) Opioid agonist and antagonist behavioral effects of buprenorphine. Br J Pharmacol 78:607–615
Leander JD (1987) Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology 26:1445–1447
Leander JD (1988) Buprenorphine is a potent kappa opioid receptor antagonist in pigeons and mice. Eur J Pharmacol (in press)
Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE (1976) The effects of morphine- and nalorphine-like drugs in the non-dependent and morphine dependent chronic spinal dog. J Pharmacol Exp Ther 197:517–532
Negus SS, Dykstra LA (1988) Kappa antagonist properties of buprenorphine in the shock titration procedure. Eur J Pharmacol 156:77–86
Richards ML, Sadee W (1985) Buprenorphine is an antagonist at the kappa opioid receptor. Pharm Res 2:178–181
Romer D, Buscher H, Hill RC, Maurer R, Petcher TJ, Welle HBA, Bakel HCCK, Akkerman AM (1980) Bremazocine: a potent, long-acting opiate kappa agonist. Life Sci 27:971–978
Sadee W, Richards ML, Grevel J, Rosenbaum JS (1983) In vivo characterization of four types of opioid binding sites in rat brain. Life Sci 33:157–162
Su TP (1985) Further demonstration of kappa opioid binding sites in the brain: evidence for heterogeneity. J Pharmacol Exp Ther 232:144–148
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Negus, S.S., Picker, M.J. & Dykstra, L.A. Kappa antagonist properties of buprenorphine in non-tolerant and morphine-tolerant rats. Psychopharmacology 98, 141–143 (1989). https://doi.org/10.1007/BF00442021
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00442021